Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Akebia Therapeutics (AKBA) Restructuring Costs (2022 - 2024)

Historic Restructuring Costs for Akebia Therapeutics (AKBA) over the last 3 years, with Q1 2024 value amounting to $58000.0.

  • Akebia Therapeutics' Restructuring Costs fell 4528.3% to $58000.0 in Q1 2024 from the same period last year, while for Dec 2024 it was $58000.0, marking a year-over-year decrease of 6795.58%. This contributed to the annual value of $58000.0 for FY2024, which is 6795.58% down from last year.
  • According to the latest figures from Q1 2024, Akebia Therapeutics' Restructuring Costs is $58000.0, which was down 4528.3% from $169000.0 recorded in Q3 2023.
  • In the past 5 years, Akebia Therapeutics' Restructuring Costs ranged from a high of $14.5 million in Q2 2022 and a low of -$94000.0 during Q2 2023
  • Over the past 3 years, Akebia Therapeutics' median Restructuring Costs value was $169000.0 (recorded in 2023), while the average stood at $2.3 million.
  • Within the past 5 years, the most significant YoY rise in Akebia Therapeutics' Restructuring Costs was 611.11% (2023), while the steepest drop was 10064.69% (2023).
  • Quarter analysis of 3 years shows Akebia Therapeutics' Restructuring Costs stood at $1.2 million in 2022, then crashed by 86.17% to $169000.0 in 2023, then crashed by 65.68% to $58000.0 in 2024.
  • Its last three reported values are $58000.0 in Q1 2024, $169000.0 for Q3 2023, and -$94000.0 during Q2 2023.